Windtree Therapeutics, Inc. · OTC:WINT

Windtree Therapeutics — Investor Presentation (February 2021)

44 slides from Windtree Therapeutics's investor presentation, Feb 19, 2021

  1. Slide 1: Windtree Therapeutics Company Overview

    Windtree Therapeutics Company Overview 2021 WINDTREE THERAPEUTICS WINT)

  2. Slide 2: Forward-Looking Statements

    ooking Statements This presentation includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements, among other things, include statements about the Company's clinic

  3. Slide 3: Windtree Therapeutics Highlights

    Windtree Therapeutics Highlights GF Biopharmaceutical and medical device company with four advanced clinical programs spanning cardiovascular and respiratory disease states (NASDAQ: WINT) G Clinical programs focused on significant markets with high unmet needs and with supportive regulatory paths: *

  4. Slide 4: Windtree Therapeutics Pipeline

    Windtree Therapeutics Pipeline Lead Products Istaroxime (Acute Heart Failure) Potential for Istaroxime Breakthrough (Early Cardiogenic Shock) designation Oral SERCA2a Activators (Chronic HF; potentially HEpEF) KL4 Surfactant-COVID 19 {COVID 19 Pilot; Possible invasive ‘Tx for RDSin neonates) AEROSUR

  5. Slide 5: Strategy for Value Creation

    Strategy for Value Creation Planned Milestones Data, then ime Acute Heart Failure Study £0P2 Mtginto Istaroxime | (sition to Phase 3) 4 'Ph3, potential [_— partnering covinasting KL4 Surfactant foarrcatr ent av Data Tring 780: AEROSURF AEROSURF Bridging Study (paid and executed by partner) ate rensi

  6. Slide 6: Istaroxime

    Istaroxime Dual Mechanism SERCA2qa Activator Acute Heart Failureand Early Cardiogenic Shock _

  7. Slide 7: Heart Failure — Large, Growing Market

    Heart Failure — Large, Growing Market The prevalence and mortality of heart failure is high and increasing > 6MU.S., 20M+ worldwide patients > #1 cause of U.S. hospitalization in patients > 65 years old; + >1.3M admissions annually (U.S.) “1.5M admissions annually (E.U.) In-patient mortality up to 7

  8. Slide 8: Acute Heart Failure — Significant Unmet Clinical Need

    Acute Heart Failure — Significant Unmet Clinical Need = Clinical objectives for AHF patient management include: * Relieve pulmonary congestion and general edema (e.g. “dry out”) with i.v. diuretics * Improve cardiac function and peripheral / organ perfusion * Achieve stable, fully compensated clinic

  9. Slide 9: Istaroxime — Novel First-in-Class Therapy

    Istaroxime — Novel First-in-Class Therapy Novel intravenous agent designed to improve systolic contraction and diastolic relaxation of the heart aca, a ahibHion of the sogiana- Stimulation of SERCA2a activity — enhances calcium reuptake resulting in potassium pumpandeffectson [StAFOXIME improvement

  10. Slide 10: Istaroxime AHF Phase 2a & 2b Studies — Summary

    Istaroxime AHF Phase 2a & 2b Studies — Summary Multicenter, double blind, placebo-controlled, parallel group in 240 patients a & n=120 Dosing= 6 hour = ADHF Patients 0.5, 1, 1.5yg/ke/min Infusion Phase n=120 Dosing= 24 hour ADHF Patients 9-5, 1.0ug/kg/min Infusion (dyspnea plus need for IV furosemid

  11. Slide 11: Primary Endpoint Achieved

    Primary Endpoint Achieved Significant Changes in E/e' Ratio!) and Stroke Volume istaroxime0.5 ug/kg/min vs. placebo istaroxime 1.0 ug/kg/min vs. placebo 2 a 10 1 oo vo 19 _ go Boo $0 y Bao ao Fe 30 0 ‘so | nfusion period info “0 = pales “ “pees + valve = 0.029 a Pras sn. Baseline hours 2éhows 48 hou

  12. Slide 12: Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve

    Systolic Blood Pressure Increased During Treatment and Renal Function Tended to Improve istaroxime 0.5 ug/kg/min vs. placebo istaroxime 1.0 pg/kg/min vs. placebo 2 ———————— : > i Systolic = 3 Blood ee 3 Pressure = ° é3 (sBP) 83 | ———__ info psd +) TTntason pened | ri * p-value=0.011, ** p-values $0,

  13. Slide 13: Heart Rate Decreased and No Increases in Cardiac Troponins

    Heart Rate Decreased and No Increases in Cardiac Troponins istaroxime 0.5 ug/kg/min vs. placebo a. 8 é es : Infusion period Looe Bo Heart 53 Rate Es 58 ee * pvalue= 0.014 6,,. 1.0 1 Soe SS SS PP Oe oP 8 me Poceoo Cohort geinirocine Ds ualke/min cTnT — 0 to 24 hours Z Cardiac TnT Fe (Myocardial ee SS

  14. Slide 14: Favorable Profile Observed with 24-hour Holter Monitoring

    Favorable Profile Observed with 24-hour Holter Monitoring May Have Protective Effect on Cardiac Arrhythmias Cina Significant Arrhythmias 120% = — Bazine Oy 1(rfuson) v2 mPiceto-Cchot1 — misaoximeo' wa/mn Clinically Significant Arrhythmias 200% Baeine ay (fusion) ice casa incre isha Ventricular Tachy

  15. Slide 15: Istaroxime — Acute Heart Failure Next Steps

    Istaroxime — Acute Heart Failure Next Steps Objective: Optimize therapy and employ study enrichment strategies to create strong Phase 3 and partnership position Execute an additional study designed to complete Phase 2 and inform Phase 3 - 300 patients, 75 centers globally* Enrich therapeutic impact

  16. Slide 16: Istaroxime Early Cardiogenic Shock

    Istaroxime Early Cardiogenic Shock Additional potential indication in active clinical development

  17. Slide 17: Early Cardiogenic Shock Treatment

    Early Cardiogenic Shock Treatment Istaroxime Potential Opportunity for Accelerated Approval Pathway Cardiogenic shock is a severe presentation of heart failure characterized by very low blood pressure and hypoperfusion accompanied by high PCWP and decreased urine output > No satisfactory pharmacolog

  18. Slide 18: Changes in SBP — Phase 2a and 2b Dose Groups

    Changes in SBP — Phase 2a and 2b Dose Groups Istaroxime Has Potential to Improve Blood Pressure and Organ Perfusion 20.0 ? 18.0 E 16.0 ‘wm 14.0 a + 12.0 2 2 10.0 2 § 80 § 60 8 = 40 a S 20 0.0 . 2a Study 2b Study 2a Study 2b Study 2a Study 0.5 g/kg/min 1.0 pg/kg/min 1.5 pg/kg/min es ‘Mean SBP at Base

  19. Slide 19: Istaroxime Early Cardiogenic Shock in Severe AHF Study

    Istaroxime Early Cardiogenic Shock in Severe AHF Study Goal: * Improve SBP with acceptable safety profile » Increased systolic and diastolic cardiac function without increasing heart rate, risk for arrythmias or myocardial oxygen demand * Support a breakthrough therapy regulatory application Ongoing

  20. Slide 20: Next Generation, Oral SERCA2a Activators

    Next Generation, Oral SERCA2a Activators Acute and Chronic Heart Failure Platform The Company also has pre-clinical programs on product candidates including: Selective SERCAZa Dual Mechanism, (SERCA2a Activators & Na+/K+) Compounds * Oral & i.v. therapies for chronic heart = “Next generation Istarox

  21. Slide 21: Summary

    Summary Potential to Create Value = Acute heart failure — large market with significant unmet need = Istaroxime—dual-mechanism therapy with positive phase 2a and 2b trial outcomes: v Improved cardiac function Y Uniquely improved SBP and renal function Y Favorable safety profile compared to existing

  22. Slide 22: Lyo Lucinactant

    Lyo Lucinactant Synthetic KL4 Surfactant Lung Injury in COVID-19 Patients

  23. Slide 23: COVID-19 and ARDS Have Significant Negative Impact on Surfactant-Related Lung Function

    COVID-19 and ARDS Have Significant Negative Impact on Surfactant- Related Lung Function Ra yeah Uses angiotensin- Surfactant is necessary for lungs to stay ‘corwerting ercjme'2 alveolar Type 2 lung cells ~ inflated and for proper gas exchange: (ACE2) for entry into host the source of surfactant Type

  24. Slide 24: Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits

    Surfactant Administration in Severe COVID-19 Lung Injury May Have Potential to Provide Significant Benefits = Synthetic KL4 surfactant may mitigate surfactant deficiency and resist widespread surfactant destruction that can Pee . occur as a result of COVID-19 = Synthetic KL4 surfactant removes any i

  25. Slide 25: Phase 2 Study of Lucinactant for Treatment of COVID-19

    Phase 2 study of Lucinactant (KL4 Surfactant) for Treatment of COVID-19 Objective: demonstrate changes in physiological parameters in COVID-19- associated lung injury and ARDS _ ¢ Upto 20 patients from 4-5 US sites id — Led by investigators at Brigham & Women’s and Duke Medical Center 5 © Dosing thr

  26. Slide 26: AEROSURF

    AEROSURF Synthetic KL4 Surfactant with Proprietary Aerosol Delivery System Respiratory Distress Syndrome (RDS) Ce

  27. Slide 27: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways = Surfactant helps keep lungs open between breaths and gas exchange = Premature infants experience respiratory distress syndrome (“RDS”) due to lungs lacking endogenous surfactant = Physicians must choose between invasive surfactant deli

  28. Slide 28: AEROSURF — Potential to Impact the Clinical Course of RDS

    AEROSURF® — Potential to Impact the Clinical Course of RDS Building Evidence From Nearly 400 Patients Studied Noninvasive RDS treatment Improved Long-Term Respiratory Outcomes Suitucaiiacian Parameters evidence of potential impact on clinical course of RDS and respiratory health of preterm infants R

  29. Slide 29: AEROSURF Program Evolution and Strategy

    AEROSURF® Program Evolution and Strategy Mitigating Risks and Strengthening Our Approach “1 Execute small (n=~80 - 90) Bridging Study to transition to EOP2 / Phase 3: + Demonstrate that new ADS works and supplement phase 2 data + Optimize dosing with more drug and shorter repeat intervals Y Transiti

  30. Slide 30: Financial Summary & Capitalization as of Sept. 30, 2020

    Financial Summary & Capitalization as of Sept. 30, 2020 = Cash & Equivalents of ~$22.4 million = Bank Debt: ~$2.4M credit facility due in March 2022 secur as of Dec. 31, 2020 Common Stock 16,921,482 Options (WAEP $15.57) 1,902,744 Warrants (WAEP $16.90) 7,228,302 Fully Diluted Equivalents 26,052,528

  31. Slide 31: Strategy for Value Generation

    Strategy for Value Generation Se “e WINDTREE Strong Clinical Execution to Deliver Milestones: Execute well our late-stage clinical programs for achievement of milestones and news flow that may be growth catalysts G Transactions: * Secure focused BD transactions for deal revenue and non-dilutive fina

  32. Slide 32: Windtree Therapeutics

    Windtree Therapeutics “Striving to Deliver Hope for a Lifetime!” SQ winotree a6

  33. Slide 33: Appendix

    Appendix

  34. Slide 34: Acute Heart Failure

    Acute Heart Failure Significant Healthcare Issue with Significant Unmet Clinical Need « Patients with low blood pressure (SBP) and peripheral hypoperfusion are high risk, challenging patients. These patients are also generally resistant to diuretic therapy and often discharged in a sub-optimal state

  35. Slide 35: Istaroxime Phase 2a (HORIZON-HF) Study

    Istaroxime Phase 2a (HORIZON-HF) Study Primary Endpoint: PCWP Significant Improvements = Multicenter, double blind, placebo- , e : controlled, doses 6-hour infusion of istaroxime 0.5, 1.0, 1.5 ug/kg/min, conducted in the EU = Hospitalized with AHF, with criteria including: © LVEF < 35% © SBP 90-150

  36. Slide 36: Istaroxime Phase 2b Adverse Events

    Istaroxime Phase 2b Adverse Events Istaroxime 0.5 Istaroxime 1.0 coord Hest aeee papas (n=42) (n=40) ‘All adverse events 23 (59.0%) 31 (75.6%) 33 (82.5%) ‘Adverse events leading to Pecial aeaia 12.6%) : 4 (10.0%) Serious adverse events 2 (63%) 2 (4.9%) 6 (15.0%) Cardiac death = : 4 (25%) Cardiogenic

  37. Slide 37: KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical H5N1 Study

    KL4 Surfactant Significantly Reduced Mortality in a Pre-Clinical HSN1 Study H5N1 Study — With and Without Anti-Viral Agent = Ferrets Infected with highly pathogenic avian (H5N1) influenza ® Results in significant viral and inflammation related lung damage that is substantially ameliorated by KL4 sur

  38. Slide 38: Evidence of KL4 Surfactant Potential Utility in COVID-19

    Evidence of KL4 Surfactant Potential Utility in COVID-19 Demonstrated Utility Across Various Respiratory Distress We have been evaluating the applicability of KL4 surfactant for multiple etiologies of lung injury as well as pandemic influenza long before the COVID-19 pandemic jonstrated Utility of K

  39. Slide 39: References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury

    References Supporting Utilization of KL4 Surfactant for the Treatment of Lung Injury Hottmane M, Kiama Wier et (2020), “Thenavel coronas 2019 (2019nCoV) user SARS cornu receptor ACE? anthecelubeprotesceTMPRSS2forentyntotorget cellst0.101/2020001 3.929082" bone 202001 31.929082. Berane A,X Mel eta (2

  40. Slide 40: Surfactant in ARDS References

    Surfactant in ARDS References 1. Gregory, Steinbere KP, SpraBaR, Gadek J, Hyer=TM, Longmore WI, eal. Bovine surfactartherapy for patients with acute respiratory distress syndrome. Am Respie Crit Care Med. 1997;155:1308-1315, 2. Wiedemann, aughman®, de BoisblancE,e al, A mult centered tralinhuman sep

  41. Slide 41: Respiratory Distress Syndrome (RDS) Current Treatment Pathways

    Respiratory Distress Syndrome (RDS) Current Treatment Pathways Premature infants experience RDS due to underdeveloped lungs lacking endogenous surfactant. Surfactant helps keep lungs open between breaths and proper gas exchange Initial treatment options include invasive and noninvasive methods: Surf

  42. Slide 42: Windtree Technology Platform — AEROSURF

    Windtree Technology Platform — AEROSURF® Proprietary Synthetic KL4 Surfactant Structurally similar to human lung surfactant Utilizing pressure and heated capillary has demonstrated Liquid KLs surfactant (intratracheal instillate) ablifty 10 anronolien Ka surface for RDS approved by the FDA lyophiliz

  43. Slide 43: Transformative Potential of AEROSURF

    Transformative Potential of AEROSURF® Surfactant nCPAP Therapy Respiratory Support Reversing surfactant deficiency has a \ profound positive impact on Avoids exposure tothe risks |! 1 henefits of traditional E Tesplration ofinvasivedelivery of | rfactant th ithout surfactant therapy Surtacton erapy

  44. Slide 44: Business Development Focus

    Business Development Focus Mid-term (Data & EOP2) Long-term! (Strategy) WINDTREE We are actively engaged in discussions with multiple companies with a proactive focus as follows: Cardiovascular Partner — China Pure SERCA2a Pharma Partner — Global AEROSURF® / KL4 Licensing ex-Asia Heart Failure Portf

Windtree Therapeutics — Investor Presentation (February 2021) on 6ix